399 Stock Overview
An investment holding company, engages in the trade of beauty equipment and products in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Innovative Pharmaceutical Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.20 |
| 52 Week High | HK$0.29 |
| 52 Week Low | HK$0.18 |
| Beta | -0.11 |
| 1 Month Change | 5.79% |
| 3 Month Change | -0.50% |
| 1 Year Change | -4.29% |
| 3 Year Change | 18.93% |
| 5 Year Change | -25.56% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
We Believe That Innovative Pharmaceutical Biotech's (HKG:399) Weak Earnings Are A Good Indicator Of Underlying Profitability
Jan 03
Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?
Aug 12Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)
Jan 05Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?
Feb 18Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.
Nov 26
Shareholder Returns
| 399 | HK Trade Distributors | HK Market | |
|---|---|---|---|
| 7D | -0.5% | -0.5% | 2.6% |
| 1Y | -4.3% | -5.4% | 26.2% |
Return vs Industry: 399 exceeded the Hong Kong Trade Distributors industry which returned -5.4% over the past year.
Return vs Market: 399 underperformed the Hong Kong Market which returned 26.2% over the past year.
Price Volatility
| 399 volatility | |
|---|---|
| 399 Average Weekly Movement | 10.2% |
| Trade Distributors Industry Average Movement | 8.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 399's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 399's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 20 | n/a | www.ipb.asia |
Innovative Pharmaceutical Biotech Limited, an investment holding company, engages in the trade of beauty equipment and products in the People’s Republic of China and Hong Kong. The company operates in two segments, Trading of Beauty Products, and Research and Development. It is also involved in the research, development, and commercialization of oral insulin products; distribution of bio-industrial products; healthcare management; and provision of genetic testing services, as well as securities investment.
Innovative Pharmaceutical Biotech Limited Fundamentals Summary
| 399 fundamental statistics | |
|---|---|
| Market cap | HK$369.91m |
| Earnings (TTM) | HK$11.46m |
| Revenue (TTM) | HK$5.90m |
32.0x
P/E Ratio62.1x
P/S RatioIs 399 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 399 income statement (TTM) | |
|---|---|
| Revenue | HK$5.90m |
| Cost of Revenue | HK$5.13m |
| Gross Profit | HK$767.00k |
| Other Expenses | -HK$10.69m |
| Earnings | HK$11.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0063 |
| Gross Margin | 13.01% |
| Net Profit Margin | 194.33% |
| Debt/Equity Ratio | 190.0% |
How did 399 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 09:57 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Innovative Pharmaceutical Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jayaprabha Dhavale | Virtua Research Inc. |